Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling
Zanjing Zhai1, Xinhua Qu, Wei Yan
1Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, The People's Republic of China.
Abstract:
Bone metastasis is a common and serious complication in advanced cancers such as breast cancer, prostate cancer, and multiple myeloma. Agents that prevent bone loss could be used to develop an alternative therapy for bone metastasis. RANKL, a member of the tumor necrosis factor superfamily, has been shown to play a significant role in cancer-associated bone loss. In this study, we examined the efficacy of the natural compound andrographolide (AP), a diterpenoid lactone isolated from the traditional Chinese and Indian medicinal plant Andrographis paniculata, in reducing breast cancer-induced osteolysis. AP prevented human breast cancer-induced bone loss by suppressing RANKL-mediated and human breast cancer cell-induced osteoclast differentiation. Molecular analysis revealed that AP prevented osteoclast function by inhibiting RANKL-induced NF-κB and ERK signaling pathway in lower dose (20 μM), as well as inducing apoptosis at higher dose (40 μM). Thus, AP is a potent inhibitor of breast cancer-induced bone metastasis.
Insights
Andrographolide (AP) effectively inhibits breast cancer bone metastasis by preventing osteoclast differentiation and function. This natural compound offers a potential therapeutic strategy for reducing cancer-induced bone loss.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Bone metastasis is a frequent complication in advanced cancers like breast and prostate cancer.
- Agents preventing bone loss are crucial for managing bone metastasis.
- Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL) is implicated in cancer-associated bone loss.
Purpose of the Study:
- To evaluate the efficacy of andrographolide (AP) in mitigating breast cancer-induced osteolysis.
- To investigate the molecular mechanisms underlying AP's action on osteoclast differentiation and function.
Main Methods:
- Assessing AP's effect on RANKL-mediated osteoclast differentiation.
- Analyzing AP's impact on NF-κB and ERK signaling pathways.
- Evaluating AP's role in inducing apoptosis in cancer cells.
Main Results:
- AP suppressed human breast cancer-induced bone loss.
- AP inhibited RANKL-mediated and cancer cell-induced osteoclast differentiation.
- AP modulated NF-κB and ERK pathways and induced apoptosis in a dose-dependent manner.
Conclusions:
- Andrographolide (AP) is a potent inhibitor of breast cancer-induced bone metastasis.
- AP demonstrates therapeutic potential by targeting osteoclast activity and cancer cell apoptosis.
- AP represents a promising natural compound for developing novel bone metastasis therapies.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
01:31Osteoclasts in Bone Remodeling
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...